Lexaria Bioscience develops innovative drug delivery platforms including DehydraTECH™ for the delivery of lipophilic molecules. It increases bio-absorption; reduces time of onset; and can reduce drug costs for orally administered bioactives.
Lexaria Bioscience develops innovative drug delivery platforms. Its patented DehydraTECH™ drug delivery technology changes the way API’s enter the bloodstream, promoting healthier ingestion methods, lower overall dosing and higher effectiveness for lipophilic active molecules. DehydraTECH increases bio-absorption; reduces time of onset; and can reduce drug costs for orally administered bioactive molecules including nicotine, vitamins, non-steroidal anti-inflammatory drugs (NSAIDs) and other molecules. Lexaria has licensed DehydraTECH to multiple companies for use in various oral application formats, including to a world-leading tobacco producer for the development of smokeless, oral-based nicotine products. Lexaria operates a licensed in-house research laboratory and holds a robust intellectual property portfolio with 16 patents granted and over 60 patents pending worldwide.
W3 Total Cache is currently running in Pro version Development mode.